Viral Vectors And Plasmid DNA Manufacturing Market Revenue, USD Billion, 2022 - 2030.

The global viral vectors and plasmid DNA manufacturing market are expected to reach USD 11.19 billion by 2030, registering a CAGR of 14.71% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growing demand for viral vectors and plasmid DNA for gene therapy has prompted leading market participants to introduce innovative and technologically advanced programs and technologies to increase plasmid DNA production. For instance, In April 2018, GE Healthcare Life Sciences announced the introduction of KUBio BSL 2, a prefabricated, modular bioprocessing facility for the manufacturing of viral vector-based vaccinations, oncolytic virus, and cell and gene therapies.

Viral Vectors And Plasmid DNA Manufacturing Market Segmentation

Grand View Research has segmented the global nucleic acid isolation and purification market on the basis of product, type, method, application, end-use, and region:

Based on the Vector Type Insights, the market is segmented into Adenovirus, Retrovirus, Adeno-Associated Virus (AAV), Lentivirus, Plasmids and Others.

• The Adeno-associated virus (AAV) segment held the highest market share of 18.86% in 2021. The increase is due to the development of ocular and orthopedic gene therapy treatment exhibiting increased efficacy and efficiency.
• Proven records of non-pathogenicity are one of the important key factors boosting their adoption and these factors are driving the segment market growth.
• ADV vectors are widely utilized as vaccines due to their ability to elicit significant humoral and T-cell responses.

Based on the Workflow Insights, the market is segmented into Upstream Manufacturing and Downstream Manufacturing.

• The downstream processing segment held the highest market share of 53.31% in 2021 owing to highly complex procedures carried out for polishing and purification of clinical grade final products.
• Development of advanced products such as the ambr 15 microbioreactor system for high-throughput upstream process development is expected to drive the segment.
• ambr 15 microbioreactor system allows efficient cell culture processing with automated experimental setup & sampling, which requires less labor & laboratory space, and time taken for cleaning and sterilization is also very less.

Based on the Application Insights, the market is segmented into Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology and Research Applications.

• The vaccinology segment held the highest market share of 24.76% in 2021.
• The ability to trigger a broad immunological response, as well as the safety profiles and ease of manufacture, are all positives.
• Though viral vectors are widely employed for vaccine production before the introduction of COVID-19, the scientific community has had to repurpose existing methodologies due to the necessity of developing a vaccine against this virus.

Based on the End-use Insights, the market is segmented into Pharmaceutical and Biopharmaceutical Companies and Research Institutes.

• The research institutes segment held the highest market share of 56.60% in 2021.
• In addition, research organizations, pharmaceutical, and biopharmaceutical companies are developing as key end-users of the market for viral vectors and plasmid DNA synthesis, contributing to an increase in the introduction of sophisticated medicines and a growing number of gene therapy-based R&D initiatives.
• Pharmaceutical and biotechnological companies are leading in terms of the use of vectors.

Based on the Disease Insights, the market is segmented into Cancer, Genetic Disorders, Infectious Diseases and Others.

• The cancer segment held the highest market share of 37.28% in 2021.
• Companies have a robust pipeline portfolio of cancer gene therapy products, which in turn is expected to boost market growth throughout the forecast period.
• A number of research studies are being carried out to study the efficiency of viral vector-based therapies used in the treatment of genetic disorders.

Viral Vectors And Plasmid DNA Manufacturing Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

Key Companies Profile & Market Share Insights

The market for viral vectors and plasmid DNA manufacturing is highly competitive with the presence of well-established as well as small and mid-sized emerging players. A prominent number of players are rapidly opting for geographical expansion, strategic collaborations, and partnerships through mergers and acquisitions in emerging and economically favorable regions. For Instance, Cobra Bio focuses on the manufacturing of scalable, and robust process strategies for the manufacture of a viral vector. The company is active in the production of lentiviral vectors, AAV, and adenoviruses.

Some prominent players in the Global Viral Vectors And Plasmid DNA Manufacturing market include:

• Merck KGaA
• Lonza
• FUJIFILM Diosynth Biotechnologies
• Thermo Fisher Scientific
• Cobra Biologics
• Catalent Inc.
• Wuxi Biologics
• Takara Bio Inc.
• Waisman Biomanufacturing
• Genezen laboratories
• Batavia Biosciences
• Miltenyi Biotec GmbH
• SIRION Biotech GmbH
• Virovek Incorporation
• BioNTech IMFS GmbH
• Audentes Therapeutics
• BioMarin Pharmaceutical
• RegenxBio, Inc.

Order a free sample PDF of the in Viral Vectors And Plasmid DNA Manufacturing Market Intelligence Study, published by Grand View Research.